<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2226">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 19, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01251887</url>
  </required_header>
  <id_info>
    <org_study_id>110028</org_study_id>
    <secondary_id>11-AA-0028</secondary_id>
    <nct_id>NCT01251887</nct_id>
  </id_info>
  <brief_title>Dietary Essential Fatty Acid Regulation of Omega-3 HUFA Metabolism; Satiety and Body Composition</brief_title>
  <official_title>Dietary Linoleic Acid Regulation of Omega-3 HUFA Metabolism: Satiety and Body Composition Among Overweight Female Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:&#xD;
&#xD;
      - Rates of obesity have increased dramatically in recent decades, and researchers are&#xD;
      investigating how changes in diets and physical activity have contributed to this increase.&#xD;
      To understand how weight might be controlled, it is important to learn what kinds of dietary&#xD;
      changes can affect hunger and might lower body weight. Essential fatty acids, for instance,&#xD;
      are an important part of a healthy diet, but researchers have not yet determined the ideal&#xD;
      amount of essential fatty acids that people should eat. By studying how different diets&#xD;
      affect body chemistry and hormone levels in women who are overweight or obese, researchers&#xD;
      hope to be able to determine better diets or treatments to help people reach and maintain an&#xD;
      optimum healthy weight.&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
      - To examine how certain fats in the diet affect body metabolism, hormones, and weight&#xD;
      regulation.&#xD;
&#xD;
      Eligibility:&#xD;
&#xD;
      - Healthy women between 18 and 50 years of age who are overweight or obese (body mass index&#xD;
      between 25 and 35).&#xD;
&#xD;
      Design:&#xD;
&#xD;
        -  This study has an initial screening visit and three phases. All participants will be&#xD;
           involved in the first two phases of the study, and some participants will be involved in&#xD;
           the third phase.&#xD;
&#xD;
        -  Participants will be screened with a physical examination and medical history, in&#xD;
           addition to blood and urine tests and questionnaires about eating habits and other diet&#xD;
           factors.&#xD;
&#xD;
        -  Phase 1: Participants will have three visits to the National Institutes of Health over a&#xD;
           4-week period. At the visits, participants will have blood and urine tests, complete&#xD;
           questionnaires, and have other tests including brain and body imaging studies.&#xD;
           Participants will then be assigned to one of three study diets.&#xD;
&#xD;
        -  Phase 2: Participants will have a 12-week diet phase, with all foods supplied by the&#xD;
           study researchers. Participants will keep a daily log of food and beverage intake, and&#xD;
           will have three testing sessions with procedures similar to those performed in Phase 1.&#xD;
&#xD;
        -  Phase 3: Participants assigned to a particular study diet (one-third of all&#xD;
           participants) will be given the option of continuing the diet for an additional 36 weeks&#xD;
           (9 months), with food consumption, monitoring, and testing procedures similar to those&#xD;
           performed in Phase 2....&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective&#xD;
&#xD;
      To evaluate the effects of lowering the dietary nutrient linoleic acid (LA) as a controlled&#xD;
      variable on: 1) tissue accretion of omega-6 and omega-3 highly unsaturated fatty acids&#xD;
      (HUFA); 2) bioactive endocannabinoids derived from the omega-6 HUFA arachidonic acid (AA); 3)&#xD;
      insulin sensitivity; 4) satiety and hunger; and 5) body composition. Modifications in dietary&#xD;
      LA will be offset with reciprocal changes in the nutrient oleic acid (OA) to maintain&#xD;
      equivalency of calories and nutrients.&#xD;
&#xD;
      Study Population&#xD;
&#xD;
      Up to 180 overweight, but otherwise healthy pre-menopausal women volunteers (aged 18 through&#xD;
      50) with body mass index (BMI) between 25 and 35 kg/m(2), will be enrolled.&#xD;
&#xD;
      With the anticipated dropout rates described in Section 7.4, we anticipate that 84 of these&#xD;
      subjects will be randomized to study diets, and 64 subjects will complete the 12 week diet&#xD;
      phase.&#xD;
&#xD;
      Three Group Comparative Analysis&#xD;
&#xD;
      A total of 84 subjects will be randomized to one of 3 healthy and nutritionally complete&#xD;
      diets that differ only in the fatty acid composition of added visible oils. All foods will be&#xD;
      provided through the NIH metabolic kitchen, with subjects visiting the kitchen daily Monday&#xD;
      through Friday to obtain foods. Each Friday, subjects will carry home foods packed for their&#xD;
      weekend meals. Baseline testing battery will include: 1) blood composition of omega-6 and&#xD;
      omega-3 HUFA; 2) endocannabinoid, eicosanoid, and docosanoid derivatives of omega-6 and&#xD;
      omega-3 HUFA; 3) insulin function assessment; 4) body composition assessment; 4) functional&#xD;
      satiety assessment; and 5) self-reported measures of satiety, hunger and affective states.&#xD;
      The full baseline testing battery will be repeated after 84 days of randomized treatment. An&#xD;
      abbreviated testing battery will be performed after 28 and 56 days of randomized treatment.&#xD;
&#xD;
      A subset of participants will undergo additional inpatient testing in the 24-hour metabolic&#xD;
      chamber as described in Section 3.3.2. The remaining subjects will remain ambulatory&#xD;
      throughout the study. Participants will be advised to continue their usual medical care and&#xD;
      medications throughout the study.&#xD;
&#xD;
      36-Week Continuation (Gradient Dose Replacement) Sub Study&#xD;
&#xD;
      At completion of the 84 day (12 week) study, participants in the low LA group (Group B) will&#xD;
      have the option of continuing their study diets for another 252 days (36 weeks). During the&#xD;
      continuation phase, the abbreviated testing battery will be completed after 6, 12, 18, 24 and&#xD;
      30 weeks, and the full testing battery will be repeated after 36 weeks.&#xD;
&#xD;
      Outcome Measures&#xD;
&#xD;
      A Primary Dependent Variables&#xD;
&#xD;
      The primary outcomes will be the proportion of omega-6 HUFA in total HUFA (%omega-6 in HUFA)&#xD;
      and two endocannabinoids derived from omega-6 AA, 2-Arachidonoylglycerol (2-AG) and&#xD;
      N-Arachidonoylethanolamine (Anandamide or AEA).&#xD;
&#xD;
      Secondary Dependent Variables&#xD;
&#xD;
      Secondary outcome measures will include blood concentrations of the omega-6 HUFA Arachidonic&#xD;
      Acid (AA); the omega-3 HUFA Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA); the&#xD;
      rates of change in %omega-6 in HUFA, AA, EPA, DHA, 2-AG and AEA over time; adipose and muscle&#xD;
      tissue fatty acid composition; endocrine hormones; gene expression profiles; psychometrics;&#xD;
      functional satiety; 24-hr energy metabolism and substrate utilization; and body composition,&#xD;
      as follows: Omega-6 and omega-3 HUFA and total fat content will be measured in adipose and&#xD;
      muscle tissue biopsies. Other endocannabinoid, eicosanoid and docosanoid derivatives of&#xD;
      omega-6 and omega-3 HUFA will be measured in plasma via mass spectrometry.&#xD;
&#xD;
      Psychometric outcomes will include self-reported measures of satiety and affective states.&#xD;
      Functional satiety will be assessed via buffet-style food array testing. Body composition&#xD;
      outcomes will include DEXA, 3T MRI, anthropometric measurements and bioelectrical impedance.&#xD;
      Genotyping will also be performed to assess for interactions between selected gene variants&#xD;
      and effects of the intervention.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 12, 2010</start_date>
  <completion_date type="Actual">July 25, 2018</completion_date>
  <primary_completion_date type="Actual">July 25, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of n-6 HUFA in Total HUFA (%n-6 in HUFA)</measure>
    <time_frame>Baseline</time_frame>
    <description>Tissue accretion of omega-6 (n-6) highly unsaturated fatty acids (HUFA) in fasting plasma as percent of total HUFA.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of n-6 HUFA in Total HUFA (%n-6 in HUFA)</measure>
    <time_frame>Week 4</time_frame>
    <description>Tissue accretion of omega-6 (n-6) highly unsaturated fatty acids (HUFA) in fasting plasma as percent of total HUFA.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of n-6 HUFA in Total HUFA (%n-6 in HUFA)</measure>
    <time_frame>Week 8</time_frame>
    <description>Tissue accretion of omega-6 (n-6) highly unsaturated fatty acids (HUFA) in fasting plasma as percent of total HUFA.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of n-6 HUFA in Total HUFA (%n-6 in HUFA)</measure>
    <time_frame>Week 12</time_frame>
    <description>Tissue accretion of omega-6 (n-6) highly unsaturated fatty acids (HUFA) in fasting plasma as percent of total HUFA.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of n-6 HUFA Arachidonic Acid (AA)</measure>
    <time_frame>Baseline</time_frame>
    <description>Tissue accretion of Arachidonic Acid (AA or 20:4n6), an omega-6 (n-6) highly unsaturated fatty acid, as measured in fasting plasma as a percent of total fatty acids.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of n-6 HUFA Arachidonic Acid (AA)</measure>
    <time_frame>Week 4</time_frame>
    <description>Tissue accretion of Arachidonic Acid (AA or 20:4n6), an omega-6 (n-6) highly unsaturated fatty acid, as measured in fasting plasma as a percent of total fatty acids.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of n-6 HUFA Arachidonic Acid (AA)</measure>
    <time_frame>Week 8</time_frame>
    <description>Tissue accretion of Arachidonic Acid (AA or 20:4n6), an omega-6 (n-6) highly unsaturated fatty acid, as measured in fasting plasma as a percent of total fatty acids.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of n-6 HUFA Arachidonic Acid (AA)</measure>
    <time_frame>Week 12</time_frame>
    <description>Tissue accretion of Arachidonic Acid (AA or 20:4n6), an omega-6 (n-6) highly unsaturated fatty acid, as measured in fasting plasma as a percent of total fatty acids.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of n-3 HUFA Eicosapentaenoic Acid (EPA)</measure>
    <time_frame>Baseline</time_frame>
    <description>Tissue accretion of eicosapentaenoic acid (EPA or 20:5n3), an omega-3 (n-3) highly unsaturated fatty acid (HUFA), as measured in fasting plasma as a percent of total fatty acids.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of n-3 HUFA Eicosapentaenoic Acid (EPA)</measure>
    <time_frame>Week 4</time_frame>
    <description>Tissue accretion of eicosapentaenoic acid (EPA or 20:5n3), an omega-3 (n-3) highly unsaturated fatty acid (HUFA), as measured in fasting plasma as a percent of total fatty acids.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of n-3 HUFA Eicosapentaenoic Acid (EPA)</measure>
    <time_frame>Week 8</time_frame>
    <description>Tissue accretion of eicosapentaenoic acid (EPA or 20:5n3), an omega-3 (n-3) highly unsaturated fatty acid (HUFA), as measured in fasting plasma as a percent of total fatty acids.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of n-3 HUFA Eicosapentaenoic Acid (EPA)</measure>
    <time_frame>Week 12</time_frame>
    <description>Tissue accretion of eicosapentaenoic acid (EPA or 20:5n3), an omega-3 (n-3) highly unsaturated fatty acid (HUFA), as measured in fasting plasma as a percent of total fatty acids.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of n-3 HUFA Docosahexaenoic Acid (DHA)</measure>
    <time_frame>Baseline</time_frame>
    <description>Tissue accretion of Docosahexaenoic Acid (DHA or 22:6n3), an omega-3 (n-3) highly unsaturated fatty acid (HUFA), as measured in fasting plasma as a percent of total fatty acids.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of n-3 HUFA Docosahexaenoic Acid (DHA)</measure>
    <time_frame>Week 4</time_frame>
    <description>Tissue accretion of Docosahexaenoic Acid (DHA or 22:6n3), an omega-3 (n-3) highly unsaturated fatty acid (HUFA), as measured in fasting plasma as a percent of total fatty acids.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of n-3 HUFA Docosahexaenoic Acid (DHA)</measure>
    <time_frame>Week 8</time_frame>
    <description>Tissue accretion of Docosahexaenoic Acid (DHA or 22:6n3), an omega-3 (n-3) highly unsaturated fatty acid (HUFA), as measured in fasting plasma as a percent of total fatty acids.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of n-3 HUFA Docosahexaenoic Acid (DHA)</measure>
    <time_frame>Week 12</time_frame>
    <description>Tissue accretion of Docosahexaenoic Acid (DHA or 22:6n3), an omega-3 (n-3) highly unsaturated fatty acid (HUFA), as measured in fasting plasma as a percent of total fatty acids.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">85</enrollment>
  <condition>Weight Gain</condition>
  <condition>Healthy Subjects</condition>
  <condition>Obesity</condition>
  <condition>Women</condition>
  <arm_group>
    <arm_group_label>Diet A: Low omega-3 (n-3) + High linoleic acid (LA)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study diet containing 8 % energy (en%) linoleic acid (LA), 0.4 % energy (en%) arachidonic acid (AA), 0.05 % omega-3 highly unsaturated fatty acids (HUFA) for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diet B: Low omega-3 (n-3) + Low linoleic acid (LA)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study diet containing 1 % energy (en%) linoleic acid (LA), 0.4 % energy (en%) arachidonic acid (AA), 0.05 % omega-3 highly unsaturated fatty acids highly unsaturated fatty acids (HUFA) for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diet C: High omega-3 (n-3) + Low linoleic acid (LA)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study diet containing 1 % energy (en%) linoleic acid (LA), 0.4 % energy (en%) arachidonic acid (AA), 0.81 % omega-3 (n-3) HUFA for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Linoleic Acid</intervention_name>
    <arm_group_label>Diet A: Low omega-3 (n-3) + High linoleic acid (LA)</arm_group_label>
    <arm_group_label>Diet B: Low omega-3 (n-3) + Low linoleic acid (LA)</arm_group_label>
    <arm_group_label>Diet C: High omega-3 (n-3) + Low linoleic acid (LA)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Docosahexaenoic Acid</intervention_name>
    <arm_group_label>Diet A: Low omega-3 (n-3) + High linoleic acid (LA)</arm_group_label>
    <arm_group_label>Diet B: Low omega-3 (n-3) + Low linoleic acid (LA)</arm_group_label>
    <arm_group_label>Diet C: High omega-3 (n-3) + Low linoleic acid (LA)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Eicosapentaenoic Acid</intervention_name>
    <arm_group_label>Diet A: Low omega-3 (n-3) + High linoleic acid (LA)</arm_group_label>
    <arm_group_label>Diet B: Low omega-3 (n-3) + Low linoleic acid (LA)</arm_group_label>
    <arm_group_label>Diet C: High omega-3 (n-3) + Low linoleic acid (LA)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:&#xD;
&#xD;
        Subjects will be overweight, but otherwise healthy, pre-menopausal ambulatory volunteers&#xD;
        aged 18 to 50.&#xD;
&#xD;
        To be eligible for this research study, participants must:&#xD;
&#xD;
          -  Be between 18 and 50 years of age.&#xD;
&#xD;
          -  Have regular menstrual cycles.&#xD;
&#xD;
          -  Be willing to use an effective method of birth control such as hormonal contraception,&#xD;
             intrauterine device, barrier methods combined with spermicide, or surgical&#xD;
             sterilization.&#xD;
&#xD;
          -  Have a body mass index of 25 to 35 kg/m(2).&#xD;
&#xD;
          -  Be otherwise healthy as determined by history, medical examination and laboratory&#xD;
             tests.&#xD;
&#xD;
          -  Be able to come to the NIH Clinical Center every weekday for 3 months.&#xD;
&#xD;
          -  Be able to understand the consent form, and provide informed written consent.&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
        Participants are not eligible for this research study if they:&#xD;
&#xD;
          -  Have been pregnant or have breast fed within the last 2 years.&#xD;
&#xD;
          -  Work, or have an immediate family member who works, with a study investigator.&#xD;
             Immediate family is defined as a spouse, parent, child or sibling, whether biological&#xD;
             or legally adopted.&#xD;
&#xD;
          -  Are HIV positive.&#xD;
&#xD;
          -  Have any current, unstable medical conditions including respiratory insufficiency&#xD;
             requiring oxygen therapy; cardiac ischemia; cardiac or hepatic failure; or acute&#xD;
             neurological illness as assessed by history and physical exam.&#xD;
&#xD;
          -  Have evidence of diseases that may influence metabolism (e.g. overt diabetes mellitus,&#xD;
             thyroid disease, cancer)&#xD;
&#xD;
          -  Have any current or past history of eating disorders such as binge eating or anorexia&#xD;
             nervosa.&#xD;
&#xD;
          -  Have had weight loss (bariatric) surgery.&#xD;
&#xD;
          -  Have gained or lost more than 3% of your current weight in the past 3 months.&#xD;
&#xD;
          -  Exercise strenuously, like running, swimming, or basketball, 4 or more times per week.&#xD;
&#xD;
          -  Are planning to begin a strenuous exercise program in the next 4 months.&#xD;
&#xD;
          -  Take supplements that contain omega-6 or omega-3 fatty acids (e.g. fish, cod liver,&#xD;
             borage, evening primrose oils)&#xD;
&#xD;
          -  Have significant dietary limitations (e.g. multiple food allergies/intolerances, vegan&#xD;
             diet) or special dietary requirements that are difficult to accommodate with study&#xD;
             diets&#xD;
&#xD;
          -  Have significant claustrophobia that would preclude study tests.&#xD;
&#xD;
          -  Have a history of alcohol or substance abuse or dependence in the past 5 years.&#xD;
&#xD;
          -  Drink more than 2 alcoholic beverages per day, on average, or 6 drinks per sitting in&#xD;
             the past year. Participants may drink up to one alcoholic beverage per day during the&#xD;
             study.&#xD;
&#xD;
          -  Used marijuana, amphetamines, cocaine, or heroin even once over the last year.&#xD;
             Participants may not use marijuana, amphetamines, cocaine, or heroin during the study.&#xD;
&#xD;
          -  Have smoked 2 or more cigarettes per week, on average, over the past year.&#xD;
&#xD;
          -  Participants may not use tobacco products during the study.&#xD;
&#xD;
          -  Eat fish 3 or more times per week on average.&#xD;
&#xD;
          -  Have a known bleeding disorder.&#xD;
&#xD;
          -  Take medications or supplements that may interfere with this study by altering energy&#xD;
             metabolism, nutrient absorption, or food intake. Regular use of the following&#xD;
             compounds warrants exclusion: medications for the management of diabetes (Type 1 or&#xD;
             2), typical and atypical antipsychotics, thyroid medications, glucocorticoids,&#xD;
             orlistat, decongestants, anti-histamines, and medications for cardiac conditions (e.g.&#xD;
             beta blockers), attention disorders (e.g. amphetamine derivatives), blood lipid&#xD;
             disorders (e.g. statins, fibrates), and hypertension (e.g. thiazide diuretics), as&#xD;
             well as certain anti-depressants (e.g. tricyclics), and supplements that impact energy&#xD;
             metabolism, such as ephedrine.&#xD;
&#xD;
          -  Regularly take an anticoagulant medication, such as warfarin or aspirin.&#xD;
&#xD;
          -  Have a pacemaker, brain stimulator, or other implanted electrical device, permanent&#xD;
             eyeliner, metallic prosthesis (including metal pins and rods, heart valves, and&#xD;
             cochlear implants) that would preclude MRI scans.&#xD;
&#xD;
          -  Are currently participating in any other clinical research studies that include blood&#xD;
             draws or other procedures.&#xD;
&#xD;
          -  Have a serum follicle-stimulating hormone (FSH) level greater than 20 units per liter&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher E Ramsden, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute on Aging (NIA)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Cota D. The role of the endocannabinoid system in the regulation of hypothalamic-pituitary-adrenal axis activity. J Neuroendocrinol. 2008 May;20 Suppl 1:35-8. doi: 10.1111/j.1365-2826.2008.01673.x. Review.</citation>
    <PMID>18426497</PMID>
  </reference>
  <reference>
    <citation>Pagotto U, Marsicano G, Cota D, Lutz B, Pasquali R. The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev. 2006 Feb;27(1):73-100. Epub 2005 Nov 23. Review.</citation>
    <PMID>16306385</PMID>
  </reference>
  <reference>
    <citation>Szmitko PE, Verma S. The endocannabinoid system and cardiometabolic risk. Atherosclerosis. 2008 Aug;199(2):248-56. doi: 10.1016/j.atherosclerosis.2008.03.011. Epub 2008 Mar 20. Review.</citation>
    <PMID>18440538</PMID>
  </reference>
  <verification_date>July 25, 2018</verification_date>
  <study_first_submitted>December 1, 2010</study_first_submitted>
  <study_first_submitted_qc>December 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2010</study_first_posted>
  <results_first_submitted>August 6, 2021</results_first_submitted>
  <results_first_submitted_qc>August 6, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">September 5, 2021</results_first_posted>
  <last_update_submitted>August 6, 2021</last_update_submitted>
  <last_update_submitted_qc>August 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lipids</keyword>
  <keyword>Obesity</keyword>
  <keyword>Omega-3 Fatty Acids</keyword>
  <keyword>Overweight</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Weight Gain</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 3, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/87/NCT01251887/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>85 subjects were consented to protocol. 19 of the 85 subjects were screen failures and one subject cancelled prior to start of study due to scheduling conflict.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Diet A: Low Omega-3 (n-3) + High Linoleic Acid (LA)</title>
          <description>Study diet containing 8 % energy (en%) linoleic acid (LA), 0.4 % energy (en%) arachidonic acid (AA), 0.05 % omega-3 highly unsaturated fatty acids (HUFA) for 12 weeks</description>
        </group>
        <group group_id="P2">
          <title>Diet B: Low Omega-3 (n-3) + Low Linoleic Acid (LA)</title>
          <description>Study diet containing 1 % energy (en%) linoleic acid (LA), 0.4 % energy (en%) arachidonic acid (AA), 0.05 % omega-3 highly unsaturated fatty acids highly unsaturated fatty acids (HUFA) for 12 weeks</description>
        </group>
        <group group_id="P3">
          <title>Diet C: High Omega-3 (n-3) + Low Linoleic Acid (LA)</title>
          <description>Study diet containing 1 % energy (en%) linoleic acid (LA), 0.4 % energy (en%) arachidonic acid (AA), 0.81 % omega-3 (n-3) HUFA for 12 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="29"/>
                <participants group_id="P3" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="26"/>
                <participants group_id="P3" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Scheduling conflict</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Diet A: Low Omega-3 (n-3) + High Linoleic Acid (LA)</title>
          <description>Study diet containing 8 % energy (en%) linoleic acid (LA), 0.4 % energy (en%) arachidonic acid (AA), 0.05 % omega-3 highly unsaturated fatty acids (HUFA) for 12 weeks</description>
        </group>
        <group group_id="B2">
          <title>Diet B: Low Omega-3 (n-3) + Low Linoleic Acid (LA)</title>
          <description>Study diet containing 1 % energy (en%) linoleic acid (LA), 0.4 % energy (en%) arachidonic acid (AA), 0.05 % omega-3 highly unsaturated fatty acids highly unsaturated fatty acids (HUFA) for 12 weeks</description>
        </group>
        <group group_id="B3">
          <title>Diet C: High Omega-3 (n-3) + Low Linoleic Acid (LA)</title>
          <description>Study diet containing 1 % energy (en%) linoleic acid (LA), 0.4 % energy (en%) arachidonic acid (AA), 0.81 % omega-3 (n-3) HUFA for 12 weeks</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
            <count group_id="B2" value="29"/>
            <count group_id="B3" value="18"/>
            <count group_id="B4" value="65"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="65"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="65"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="56"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Proportion of n-6 HUFA in Total HUFA (%n-6 in HUFA)</title>
        <description>Tissue accretion of omega-6 (n-6) highly unsaturated fatty acids (HUFA) in fasting plasma as percent of total HUFA.</description>
        <time_frame>Baseline</time_frame>
        <population>The analyses included only those participants who completed at least 4 weeks of the diet phase with fasting blood samples available</population>
        <group_list>
          <group group_id="O1">
            <title>Diet A: Low Omega-3 (n-3) + High Linoleic Acid (LA)</title>
            <description>Study diet containing 8 % energy (en%) linoleic acid (LA), 0.4 % energy (en%) arachidonic acid (AA), 0.05 % omega-3 highly unsaturated fatty acids (HUFA) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Diet B: Low Omega-3 (n-3) + Low Linoleic Acid (LA)</title>
            <description>Study diet containing 1 % energy (en%) linoleic acid (LA), 0.4 % energy (en%) arachidonic acid (AA), 0.05 % omega-3 highly unsaturated fatty acids highly unsaturated fatty acids (HUFA) for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>Diet C: High Omega-3 (n-3) + Low Linoleic Acid (LA)</title>
            <description>Study diet containing 1 % energy (en%) linoleic acid (LA), 0.4 % energy (en%) arachidonic acid (AA), 0.81 % omega-3 (n-3) HUFA for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of n-6 HUFA in Total HUFA (%n-6 in HUFA)</title>
          <description>Tissue accretion of omega-6 (n-6) highly unsaturated fatty acids (HUFA) in fasting plasma as percent of total HUFA.</description>
          <population>The analyses included only those participants who completed at least 4 weeks of the diet phase with fasting blood samples available</population>
          <units>Percentage of total HUFA</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.0" spread="1.2"/>
                    <measurement group_id="O2" value="81.3" spread="0.9"/>
                    <measurement group_id="O3" value="80.5" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Proportion of n-6 HUFA in Total HUFA (%n-6 in HUFA)</title>
        <description>Tissue accretion of omega-6 (n-6) highly unsaturated fatty acids (HUFA) in fasting plasma as percent of total HUFA.</description>
        <time_frame>Week 4</time_frame>
        <population>The analyses included only those participants who completed at least 4 weeks of the diet phase with fasting blood samples available</population>
        <group_list>
          <group group_id="O1">
            <title>Diet A: Low Omega-3 (n-3) + High Linoleic Acid (LA)</title>
            <description>Study diet containing 8 % energy (en%) linoleic acid (LA), 0.4 % energy (en%) arachidonic acid (AA), 0.05 % omega-3 highly unsaturated fatty acids (HUFA) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Diet B: Low Omega-3 (n-3) + Low Linoleic Acid (LA)</title>
            <description>Study diet containing 1 % energy (en%) linoleic acid (LA), 0.4 % energy (en%) arachidonic acid (AA), 0.05 % omega-3 highly unsaturated fatty acids highly unsaturated fatty acids (HUFA) for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>Diet C: High Omega-3 (n-3) + Low Linoleic Acid (LA)</title>
            <description>Study diet containing 1 % energy (en%) linoleic acid (LA), 0.4 % energy (en%) arachidonic acid (AA), 0.81 % omega-3 (n-3) HUFA for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of n-6 HUFA in Total HUFA (%n-6 in HUFA)</title>
          <description>Tissue accretion of omega-6 (n-6) highly unsaturated fatty acids (HUFA) in fasting plasma as percent of total HUFA.</description>
          <population>The analyses included only those participants who completed at least 4 weeks of the diet phase with fasting blood samples available</population>
          <units>Percentage of total HUFA</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80" spread="1.1"/>
                    <measurement group_id="O2" value="80.7" spread="0.9"/>
                    <measurement group_id="O3" value="70.6" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Proportion of n-6 HUFA in Total HUFA (%n-6 in HUFA)</title>
        <description>Tissue accretion of omega-6 (n-6) highly unsaturated fatty acids (HUFA) in fasting plasma as percent of total HUFA.</description>
        <time_frame>Week 8</time_frame>
        <population>The analyses included only those participants who completed at least 4 weeks of the diet phase with fasting blood samples available</population>
        <group_list>
          <group group_id="O1">
            <title>Diet A: Low Omega-3 (n-3) + High Linoleic Acid (LA)</title>
            <description>Study diet containing 8 % energy (en%) linoleic acid (LA), 0.4 % energy (en%) arachidonic acid (AA), 0.05 % omega-3 highly unsaturated fatty acids (HUFA) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Diet B: Low Omega-3 (n-3) + Low Linoleic Acid (LA)</title>
            <description>Study diet containing 1 % energy (en%) linoleic acid (LA), 0.4 % energy (en%) arachidonic acid (AA), 0.05 % omega-3 highly unsaturated fatty acids highly unsaturated fatty acids (HUFA) for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>Diet C: High Omega-3 (n-3) + Low Linoleic Acid (LA)</title>
            <description>Study diet containing 1 % energy (en%) linoleic acid (LA), 0.4 % energy (en%) arachidonic acid (AA), 0.81 % omega-3 (n-3) HUFA for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of n-6 HUFA in Total HUFA (%n-6 in HUFA)</title>
          <description>Tissue accretion of omega-6 (n-6) highly unsaturated fatty acids (HUFA) in fasting plasma as percent of total HUFA.</description>
          <population>The analyses included only those participants who completed at least 4 weeks of the diet phase with fasting blood samples available</population>
          <units>Percentage of total HUFA</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.7" spread="1.2"/>
                    <measurement group_id="O2" value="80.6" spread="0.9"/>
                    <measurement group_id="O3" value="70.8" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Proportion of n-6 HUFA in Total HUFA (%n-6 in HUFA)</title>
        <description>Tissue accretion of omega-6 (n-6) highly unsaturated fatty acids (HUFA) in fasting plasma as percent of total HUFA.</description>
        <time_frame>Week 12</time_frame>
        <population>The analyses included only those participants who completed at least 4 weeks of the diet phase with fasting blood samples available</population>
        <group_list>
          <group group_id="O1">
            <title>Diet A: Low Omega-3 (n-3) + High Linoleic Acid (LA)</title>
            <description>Study diet containing 8 % energy (en%) linoleic acid (LA), 0.4 % energy (en%) arachidonic acid (AA), 0.05 % omega-3 highly unsaturated fatty acids (HUFA) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Diet B: Low Omega-3 (n-3) + Low Linoleic Acid (LA)</title>
            <description>Study diet containing 1 % energy (en%) linoleic acid (LA), 0.4 % energy (en%) arachidonic acid (AA), 0.05 % omega-3 highly unsaturated fatty acids highly unsaturated fatty acids (HUFA) for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>Diet C: High Omega-3 (n-3) + Low Linoleic Acid (LA)</title>
            <description>Study diet containing 1 % energy (en%) linoleic acid (LA), 0.4 % energy (en%) arachidonic acid (AA), 0.81 % omega-3 (n-3) HUFA for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of n-6 HUFA in Total HUFA (%n-6 in HUFA)</title>
          <description>Tissue accretion of omega-6 (n-6) highly unsaturated fatty acids (HUFA) in fasting plasma as percent of total HUFA.</description>
          <population>The analyses included only those participants who completed at least 4 weeks of the diet phase with fasting blood samples available</population>
          <units>Percentage of total HUFA</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.6" spread="1.1"/>
                    <measurement group_id="O2" value="81" spread="0.9"/>
                    <measurement group_id="O3" value="72.9" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of n-6 HUFA Arachidonic Acid (AA)</title>
        <description>Tissue accretion of Arachidonic Acid (AA or 20:4n6), an omega-6 (n-6) highly unsaturated fatty acid, as measured in fasting plasma as a percent of total fatty acids.</description>
        <time_frame>Baseline</time_frame>
        <population>The analyses included only those participants who completed at least 4 weeks of the diet phase with fasting blood samples available</population>
        <group_list>
          <group group_id="O1">
            <title>Diet A: Low Omega-3 (n-3) + High Linoleic Acid (LA)</title>
            <description>Study diet containing 8 % energy (en%) linoleic acid (LA), 0.4 % energy (en%) arachidonic acid (AA), 0.05 % omega-3 highly unsaturated fatty acids (HUFA) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Diet B: Low Omega-3 (n-3) + Low Linoleic Acid (LA)</title>
            <description>Study diet containing 1 % energy (en%) linoleic acid (LA), 0.4 % energy (en%) arachidonic acid (AA), 0.05 % omega-3 highly unsaturated fatty acids highly unsaturated fatty acids (HUFA) for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>Diet C: High Omega-3 (n-3) + Low Linoleic Acid (LA)</title>
            <description>Study diet containing 1 % energy (en%) linoleic acid (LA), 0.4 % energy (en%) arachidonic acid (AA), 0.81 % omega-3 (n-3) HUFA for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of n-6 HUFA Arachidonic Acid (AA)</title>
          <description>Tissue accretion of Arachidonic Acid (AA or 20:4n6), an omega-6 (n-6) highly unsaturated fatty acid, as measured in fasting plasma as a percent of total fatty acids.</description>
          <population>The analyses included only those participants who completed at least 4 weeks of the diet phase with fasting blood samples available</population>
          <units>Percentage of total fatty acids</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.42" spread="0.3"/>
                    <measurement group_id="O2" value="6.51" spread="0.22"/>
                    <measurement group_id="O3" value="7.12" spread="0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of n-6 HUFA Arachidonic Acid (AA)</title>
        <description>Tissue accretion of Arachidonic Acid (AA or 20:4n6), an omega-6 (n-6) highly unsaturated fatty acid, as measured in fasting plasma as a percent of total fatty acids.</description>
        <time_frame>Week 4</time_frame>
        <population>The analyses included only those participants who completed at least 4 weeks of the diet phase with fasting blood samples available</population>
        <group_list>
          <group group_id="O1">
            <title>Diet A: Low Omega-3 (n-3) + High Linoleic Acid (LA)</title>
            <description>Study diet containing 8 % energy (en%) linoleic acid (LA), 0.4 % energy (en%) arachidonic acid (AA), 0.05 % omega-3 highly unsaturated fatty acids (HUFA) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Diet B: Low Omega-3 (n-3) + Low Linoleic Acid (LA)</title>
            <description>Study diet containing 1 % energy (en%) linoleic acid (LA), 0.4 % energy (en%) arachidonic acid (AA), 0.05 % omega-3 highly unsaturated fatty acids highly unsaturated fatty acids (HUFA) for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>Diet C: High Omega-3 (n-3) + Low Linoleic Acid (LA)</title>
            <description>Study diet containing 1 % energy (en%) linoleic acid (LA), 0.4 % energy (en%) arachidonic acid (AA), 0.81 % omega-3 (n-3) HUFA for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of n-6 HUFA Arachidonic Acid (AA)</title>
          <description>Tissue accretion of Arachidonic Acid (AA or 20:4n6), an omega-6 (n-6) highly unsaturated fatty acid, as measured in fasting plasma as a percent of total fatty acids.</description>
          <population>The analyses included only those participants who completed at least 4 weeks of the diet phase with fasting blood samples available</population>
          <units>Percentage of total fatty acids</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.25" spread="0.29"/>
                    <measurement group_id="O2" value="7.02" spread="0.22"/>
                    <measurement group_id="O3" value="6.37" spread="0.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of n-6 HUFA Arachidonic Acid (AA)</title>
        <description>Tissue accretion of Arachidonic Acid (AA or 20:4n6), an omega-6 (n-6) highly unsaturated fatty acid, as measured in fasting plasma as a percent of total fatty acids.</description>
        <time_frame>Week 8</time_frame>
        <population>The analyses included only those participants who completed at least 4 weeks of the diet phase with fasting blood samples available</population>
        <group_list>
          <group group_id="O1">
            <title>Diet A: Low Omega-3 (n-3) + High Linoleic Acid (LA)</title>
            <description>Study diet containing 8 % energy (en%) linoleic acid (LA), 0.4 % energy (en%) arachidonic acid (AA), 0.05 % omega-3 highly unsaturated fatty acids (HUFA) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Diet B: Low Omega-3 (n-3) + Low Linoleic Acid (LA)</title>
            <description>Study diet containing 1 % energy (en%) linoleic acid (LA), 0.4 % energy (en%) arachidonic acid (AA), 0.05 % omega-3 highly unsaturated fatty acids highly unsaturated fatty acids (HUFA) for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>Diet C: High Omega-3 (n-3) + Low Linoleic Acid (LA)</title>
            <description>Study diet containing 1 % energy (en%) linoleic acid (LA), 0.4 % energy (en%) arachidonic acid (AA), 0.81 % omega-3 (n-3) HUFA for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of n-6 HUFA Arachidonic Acid (AA)</title>
          <description>Tissue accretion of Arachidonic Acid (AA or 20:4n6), an omega-6 (n-6) highly unsaturated fatty acid, as measured in fasting plasma as a percent of total fatty acids.</description>
          <population>The analyses included only those participants who completed at least 4 weeks of the diet phase with fasting blood samples available</population>
          <units>Percentage of total fatty acids</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.59" spread="0.30"/>
                    <measurement group_id="O2" value="7.27" spread="0.23"/>
                    <measurement group_id="O3" value="6.40" spread="0.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of n-6 HUFA Arachidonic Acid (AA)</title>
        <description>Tissue accretion of Arachidonic Acid (AA or 20:4n6), an omega-6 (n-6) highly unsaturated fatty acid, as measured in fasting plasma as a percent of total fatty acids.</description>
        <time_frame>Week 12</time_frame>
        <population>The analyses included only those participants who completed at least 4 weeks of the diet phase with fasting blood samples available</population>
        <group_list>
          <group group_id="O1">
            <title>Diet A: Low Omega-3 (n-3) + High Linoleic Acid (LA)</title>
            <description>Study diet containing 8 % energy (en%) linoleic acid (LA), 0.4 % energy (en%) arachidonic acid (AA), 0.05 % omega-3 highly unsaturated fatty acids (HUFA) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Diet B: Low Omega-3 (n-3) + Low Linoleic Acid (LA)</title>
            <description>Study diet containing 1 % energy (en%) linoleic acid (LA), 0.4 % energy (en%) arachidonic acid (AA), 0.05 % omega-3 highly unsaturated fatty acids highly unsaturated fatty acids (HUFA) for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>Diet C: High Omega-3 (n-3) + Low Linoleic Acid (LA)</title>
            <description>Study diet containing 1 % energy (en%) linoleic acid (LA), 0.4 % energy (en%) arachidonic acid (AA), 0.81 % omega-3 (n-3) HUFA for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of n-6 HUFA Arachidonic Acid (AA)</title>
          <description>Tissue accretion of Arachidonic Acid (AA or 20:4n6), an omega-6 (n-6) highly unsaturated fatty acid, as measured in fasting plasma as a percent of total fatty acids.</description>
          <population>The analyses included only those participants who completed at least 4 weeks of the diet phase with fasting blood samples available</population>
          <units>Percentage of total fatty acids</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.45" spread="0.29"/>
                    <measurement group_id="O2" value="7.02" spread="0.22"/>
                    <measurement group_id="O3" value="6.21" spread="0.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of n-3 HUFA Eicosapentaenoic Acid (EPA)</title>
        <description>Tissue accretion of eicosapentaenoic acid (EPA or 20:5n3), an omega-3 (n-3) highly unsaturated fatty acid (HUFA), as measured in fasting plasma as a percent of total fatty acids.</description>
        <time_frame>Baseline</time_frame>
        <population>The analyses included only those participants who completed at least 4 weeks of the diet phase with fasting blood samples available</population>
        <group_list>
          <group group_id="O1">
            <title>Diet A: Low Omega-3 (n-3) + High Linoleic Acid (LA)</title>
            <description>Study diet containing 8 % energy (en%) linoleic acid (LA), 0.4 % energy (en%) arachidonic acid (AA), 0.05 % omega-3 highly unsaturated fatty acids (HUFA) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Diet B: Low Omega-3 (n-3) + Low Linoleic Acid (LA)</title>
            <description>Study diet containing 1 % energy (en%) linoleic acid (LA), 0.4 % energy (en%) arachidonic acid (AA), 0.05 % omega-3 highly unsaturated fatty acids highly unsaturated fatty acids (HUFA) for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>Diet C: High Omega-3 (n-3) + Low Linoleic Acid (LA)</title>
            <description>Study diet containing 1 % energy (en%) linoleic acid (LA), 0.4 % energy (en%) arachidonic acid (AA), 0.81 % omega-3 (n-3) HUFA for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of n-3 HUFA Eicosapentaenoic Acid (EPA)</title>
          <description>Tissue accretion of eicosapentaenoic acid (EPA or 20:5n3), an omega-3 (n-3) highly unsaturated fatty acid (HUFA), as measured in fasting plasma as a percent of total fatty acids.</description>
          <population>The analyses included only those participants who completed at least 4 weeks of the diet phase with fasting blood samples available</population>
          <units>Percentage of total fatty acids</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.434" spread="0.065"/>
                    <measurement group_id="O2" value="0.455" spread="0.046"/>
                    <measurement group_id="O3" value="0.504" spread="0.062"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of n-3 HUFA Eicosapentaenoic Acid (EPA)</title>
        <description>Tissue accretion of eicosapentaenoic acid (EPA or 20:5n3), an omega-3 (n-3) highly unsaturated fatty acid (HUFA), as measured in fasting plasma as a percent of total fatty acids.</description>
        <time_frame>Week 4</time_frame>
        <population>The analyses included only those participants who completed at least 4 weeks of the diet phase with fasting blood samples available</population>
        <group_list>
          <group group_id="O1">
            <title>Diet A: Low Omega-3 (n-3) + High Linoleic Acid (LA)</title>
            <description>Study diet containing 8 % energy (en%) linoleic acid (LA), 0.4 % energy (en%) arachidonic acid (AA), 0.05 % omega-3 highly unsaturated fatty acids (HUFA) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Diet B: Low Omega-3 (n-3) + Low Linoleic Acid (LA)</title>
            <description>Study diet containing 1 % energy (en%) linoleic acid (LA), 0.4 % energy (en%) arachidonic acid (AA), 0.05 % omega-3 highly unsaturated fatty acids highly unsaturated fatty acids (HUFA) for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>Diet C: High Omega-3 (n-3) + Low Linoleic Acid (LA)</title>
            <description>Study diet containing 1 % energy (en%) linoleic acid (LA), 0.4 % energy (en%) arachidonic acid (AA), 0.81 % omega-3 (n-3) HUFA for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of n-3 HUFA Eicosapentaenoic Acid (EPA)</title>
          <description>Tissue accretion of eicosapentaenoic acid (EPA or 20:5n3), an omega-3 (n-3) highly unsaturated fatty acid (HUFA), as measured in fasting plasma as a percent of total fatty acids.</description>
          <population>The analyses included only those participants who completed at least 4 weeks of the diet phase with fasting blood samples available</population>
          <units>Percentage of total fatty acids</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.356" spread="0.061"/>
                    <measurement group_id="O2" value="0.479" spread="0.047"/>
                    <measurement group_id="O3" value="0.927" spread="0.061"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of n-3 HUFA Eicosapentaenoic Acid (EPA)</title>
        <description>Tissue accretion of eicosapentaenoic acid (EPA or 20:5n3), an omega-3 (n-3) highly unsaturated fatty acid (HUFA), as measured in fasting plasma as a percent of total fatty acids.</description>
        <time_frame>Week 8</time_frame>
        <population>The analyses included only those participants who completed at least 4 weeks of the diet phase with fasting blood samples available</population>
        <group_list>
          <group group_id="O1">
            <title>Diet A: Low Omega-3 (n-3) + High Linoleic Acid (LA)</title>
            <description>Study diet containing 8 % energy (en%) linoleic acid (LA), 0.4 % energy (en%) arachidonic acid (AA), 0.05 % omega-3 highly unsaturated fatty acids (HUFA) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Diet B: Low Omega-3 (n-3) + Low Linoleic Acid (LA)</title>
            <description>Study diet containing 1 % energy (en%) linoleic acid (LA), 0.4 % energy (en%) arachidonic acid (AA), 0.05 % omega-3 highly unsaturated fatty acids highly unsaturated fatty acids (HUFA) for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>Diet C: High Omega-3 (n-3) + Low Linoleic Acid (LA)</title>
            <description>Study diet containing 1 % energy (en%) linoleic acid (LA), 0.4 % energy (en%) arachidonic acid (AA), 0.81 % omega-3 (n-3) HUFA for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of n-3 HUFA Eicosapentaenoic Acid (EPA)</title>
          <description>Tissue accretion of eicosapentaenoic acid (EPA or 20:5n3), an omega-3 (n-3) highly unsaturated fatty acid (HUFA), as measured in fasting plasma as a percent of total fatty acids.</description>
          <population>The analyses included only those participants who completed at least 4 weeks of the diet phase with fasting blood samples available</population>
          <units>Percentage of total fatty acids</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.324" spread="0.064"/>
                    <measurement group_id="O2" value="0.452" spread="0.051"/>
                    <measurement group_id="O3" value="0.806" spread="0.061"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of n-3 HUFA Eicosapentaenoic Acid (EPA)</title>
        <description>Tissue accretion of eicosapentaenoic acid (EPA or 20:5n3), an omega-3 (n-3) highly unsaturated fatty acid (HUFA), as measured in fasting plasma as a percent of total fatty acids.</description>
        <time_frame>Week 12</time_frame>
        <population>The analyses included only those participants who completed at least 4 weeks of the diet phase with fasting blood samples available</population>
        <group_list>
          <group group_id="O1">
            <title>Diet A: Low Omega-3 (n-3) + High Linoleic Acid (LA)</title>
            <description>Study diet containing 8 % energy (en%) linoleic acid (LA), 0.4 % energy (en%) arachidonic acid (AA), 0.05 % omega-3 highly unsaturated fatty acids (HUFA) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Diet B: Low Omega-3 (n-3) + Low Linoleic Acid (LA)</title>
            <description>Study diet containing 1 % energy (en%) linoleic acid (LA), 0.4 % energy (en%) arachidonic acid (AA), 0.05 % omega-3 highly unsaturated fatty acids highly unsaturated fatty acids (HUFA) for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>Diet C: High Omega-3 (n-3) + Low Linoleic Acid (LA)</title>
            <description>Study diet containing 1 % energy (en%) linoleic acid (LA), 0.4 % energy (en%) arachidonic acid (AA), 0.81 % omega-3 (n-3) HUFA for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of n-3 HUFA Eicosapentaenoic Acid (EPA)</title>
          <description>Tissue accretion of eicosapentaenoic acid (EPA or 20:5n3), an omega-3 (n-3) highly unsaturated fatty acid (HUFA), as measured in fasting plasma as a percent of total fatty acids.</description>
          <population>The analyses included only those participants who completed at least 4 weeks of the diet phase with fasting blood samples available</population>
          <units>Percentage of total fatty acids</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.338" spread="0.061"/>
                    <measurement group_id="O2" value="0.388" spread="0.048"/>
                    <measurement group_id="O3" value="0.707" spread="0.062"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of n-3 HUFA Docosahexaenoic Acid (DHA)</title>
        <description>Tissue accretion of Docosahexaenoic Acid (DHA or 22:6n3), an omega-3 (n-3) highly unsaturated fatty acid (HUFA), as measured in fasting plasma as a percent of total fatty acids.</description>
        <time_frame>Baseline</time_frame>
        <population>The analyses included only those participants who completed at least 4 weeks of the diet phase with fasting blood samples available</population>
        <group_list>
          <group group_id="O1">
            <title>Diet A: Low Omega-3 (n-3) + High Linoleic Acid (LA)</title>
            <description>Study diet containing 8 % energy (en%) linoleic acid (LA), 0.4 % energy (en%) arachidonic acid (AA), 0.05 % omega-3 highly unsaturated fatty acids (HUFA) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Diet B: Low Omega-3 (n-3) + Low Linoleic Acid (LA)</title>
            <description>Study diet containing 1 % energy (en%) linoleic acid (LA), 0.4 % energy (en%) arachidonic acid (AA), 0.05 % omega-3 highly unsaturated fatty acids highly unsaturated fatty acids (HUFA) for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>Diet C: High Omega-3 (n-3) + Low Linoleic Acid (LA)</title>
            <description>Study diet containing 1 % energy (en%) linoleic acid (LA), 0.4 % energy (en%) arachidonic acid (AA), 0.81 % omega-3 (n-3) HUFA for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of n-3 HUFA Docosahexaenoic Acid (DHA)</title>
          <description>Tissue accretion of Docosahexaenoic Acid (DHA or 22:6n3), an omega-3 (n-3) highly unsaturated fatty acid (HUFA), as measured in fasting plasma as a percent of total fatty acids.</description>
          <population>The analyses included only those participants who completed at least 4 weeks of the diet phase with fasting blood samples available</population>
          <units>Percentage of total fatty acids</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.30" spread="0.11"/>
                    <measurement group_id="O2" value="1.16" spread="0.08"/>
                    <measurement group_id="O3" value="1.41" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of n-3 HUFA Docosahexaenoic Acid (DHA)</title>
        <description>Tissue accretion of Docosahexaenoic Acid (DHA or 22:6n3), an omega-3 (n-3) highly unsaturated fatty acid (HUFA), as measured in fasting plasma as a percent of total fatty acids.</description>
        <time_frame>Week 4</time_frame>
        <population>The analyses included only those participants who completed at least 4 weeks of the diet phase with fasting blood samples available</population>
        <group_list>
          <group group_id="O1">
            <title>Diet A: Low Omega-3 (n-3) + High Linoleic Acid (LA)</title>
            <description>Study diet containing 8 % energy (en%) linoleic acid (LA), 0.4 % energy (en%) arachidonic acid (AA), 0.05 % omega-3 highly unsaturated fatty acids (HUFA) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Diet B: Low Omega-3 (n-3) + Low Linoleic Acid (LA)</title>
            <description>Study diet containing 1 % energy (en%) linoleic acid (LA), 0.4 % energy (en%) arachidonic acid (AA), 0.05 % omega-3 highly unsaturated fatty acids highly unsaturated fatty acids (HUFA) for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>Diet C: High Omega-3 (n-3) + Low Linoleic Acid (LA)</title>
            <description>Study diet containing 1 % energy (en%) linoleic acid (LA), 0.4 % energy (en%) arachidonic acid (AA), 0.81 % omega-3 (n-3) HUFA for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of n-3 HUFA Docosahexaenoic Acid (DHA)</title>
          <description>Tissue accretion of Docosahexaenoic Acid (DHA or 22:6n3), an omega-3 (n-3) highly unsaturated fatty acid (HUFA), as measured in fasting plasma as a percent of total fatty acids.</description>
          <population>The analyses included only those participants who completed at least 4 weeks of the diet phase with fasting blood samples available</population>
          <units>Percentage of total fatty acids</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.39" spread="0.11"/>
                    <measurement group_id="O2" value="1.38" spread="0.08"/>
                    <measurement group_id="O3" value="2.25" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of n-3 HUFA Docosahexaenoic Acid (DHA)</title>
        <description>Tissue accretion of Docosahexaenoic Acid (DHA or 22:6n3), an omega-3 (n-3) highly unsaturated fatty acid (HUFA), as measured in fasting plasma as a percent of total fatty acids.</description>
        <time_frame>Week 8</time_frame>
        <population>The analyses included only those participants who completed at least 4 weeks of the diet phase with fasting blood samples available</population>
        <group_list>
          <group group_id="O1">
            <title>Diet A: Low Omega-3 (n-3) + High Linoleic Acid (LA)</title>
            <description>Study diet containing 8 % energy (en%) linoleic acid (LA), 0.4 % energy (en%) arachidonic acid (AA), 0.05 % omega-3 highly unsaturated fatty acids (HUFA) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Diet B: Low Omega-3 (n-3) + Low Linoleic Acid (LA)</title>
            <description>Study diet containing 1 % energy (en%) linoleic acid (LA), 0.4 % energy (en%) arachidonic acid (AA), 0.05 % omega-3 highly unsaturated fatty acids highly unsaturated fatty acids (HUFA) for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>Diet C: High Omega-3 (n-3) + Low Linoleic Acid (LA)</title>
            <description>Study diet containing 1 % energy (en%) linoleic acid (LA), 0.4 % energy (en%) arachidonic acid (AA), 0.81 % omega-3 (n-3) HUFA for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of n-3 HUFA Docosahexaenoic Acid (DHA)</title>
          <description>Tissue accretion of Docosahexaenoic Acid (DHA or 22:6n3), an omega-3 (n-3) highly unsaturated fatty acid (HUFA), as measured in fasting plasma as a percent of total fatty acids.</description>
          <population>The analyses included only those participants who completed at least 4 weeks of the diet phase with fasting blood samples available</population>
          <units>Percentage of total fatty acids</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.48" spread="0.11"/>
                    <measurement group_id="O2" value="1.44" spread="0.09"/>
                    <measurement group_id="O3" value="2.13" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of n-3 HUFA Docosahexaenoic Acid (DHA)</title>
        <description>Tissue accretion of Docosahexaenoic Acid (DHA or 22:6n3), an omega-3 (n-3) highly unsaturated fatty acid (HUFA), as measured in fasting plasma as a percent of total fatty acids.</description>
        <time_frame>Week 12</time_frame>
        <population>The analyses included only those participants who completed at least 4 weeks of the diet phase with fasting blood samples available</population>
        <group_list>
          <group group_id="O1">
            <title>Diet A: Low Omega-3 (n-3) + High Linoleic Acid (LA)</title>
            <description>Study diet containing 8 % energy (en%) linoleic acid (LA), 0.4 % energy (en%) arachidonic acid (AA), 0.05 % omega-3 highly unsaturated fatty acids (HUFA) for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Diet B: Low Omega-3 (n-3) + Low Linoleic Acid (LA)</title>
            <description>Study diet containing 1 % energy (en%) linoleic acid (LA), 0.4 % energy (en%) arachidonic acid (AA), 0.05 % omega-3 highly unsaturated fatty acids highly unsaturated fatty acids (HUFA) for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>Diet C: High Omega-3 (n-3) + Low Linoleic Acid (LA)</title>
            <description>Study diet containing 1 % energy (en%) linoleic acid (LA), 0.4 % energy (en%) arachidonic acid (AA), 0.81 % omega-3 (n-3) HUFA for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of n-3 HUFA Docosahexaenoic Acid (DHA)</title>
          <description>Tissue accretion of Docosahexaenoic Acid (DHA or 22:6n3), an omega-3 (n-3) highly unsaturated fatty acid (HUFA), as measured in fasting plasma as a percent of total fatty acids.</description>
          <population>The analyses included only those participants who completed at least 4 weeks of the diet phase with fasting blood samples available</population>
          <units>Percentage of total fatty acids</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.40" spread="0.11"/>
                    <measurement group_id="O2" value="1.38" spread="0.09"/>
                    <measurement group_id="O3" value="1.99" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 Weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Diet A: Low Omega-3 (n-3) + High Linoleic Acid (LA)</title>
          <description>Study diet containing 8 % energy (en%) linoleic acid (LA), 0.4 % energy (en%) arachidonic acid (AA), 0.05 % omega-3 highly unsaturated fatty acids (HUFA) for 12 weeks</description>
        </group>
        <group group_id="E2">
          <title>Diet B: Low Omega-3 (n-3) + Low Linoleic Acid (LA)</title>
          <description>Study diet containing 1 % energy (en%) linoleic acid (LA), 0.4 % energy (en%) arachidonic acid (AA), 0.05 % omega-3 highly unsaturated fatty acids highly unsaturated fatty acids (HUFA) for 12 weeks</description>
        </group>
        <group group_id="E3">
          <title>Diet C: High Omega-3 (n-3) + Low Linoleic Acid (LA)</title>
          <description>Study diet containing 1 % energy (en%) linoleic acid (LA), 0.4 % energy (en%) arachidonic acid (AA), 0.81 % omega-3 (n-3) HUFA for 12 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ramsden, Christopher</name_or_title>
      <organization>NIAAA/NIA</organization>
      <phone>+1 410 558 8369</phone>
      <email>ramsdence@mail.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

